GERMANTOWN, Md., May 18, 2017 /PRNewswire/ -- Intrexon
Corporation (NYSE: XON), a leader in the engineering and
industrialization of biology to improve the quality of life and
health of the planet, today announced the appointment of
Mark Carnegie-Brown, Ph.D. as Chief
Executive Officer of its wholly owned subsidiary Oxitec Ltd.
Dr. Carnegie-Brown succeeds Hadyn
Parry, who has been appointed Vice President, Corporate
Development Europe, the Middle
East, and Africa (EMEA) for
Intrexon to strengthen its management ranks abroad as it continues
to expand its global presence.
"I am delighted to be joining Oxitec and look forward to
advancing its pioneering solutions including Friendly™ Aedes," Dr.
Carnegie-Brown stated. "I believe the Company's technology
represents a paradigm shift in controlling both disease-carrying
insects, including dangerous Aedes aegypti mosquitoes, and
damaging agricultural pests that are increasingly resistant to
chemical insecticides."
Dr. Carnegie-Brown joins Oxitec with over 25 years leadership in
the life science and health science industries. This includes
strategic and operational experience in agrochemicals, drug
development, contract manufacturing and drug delivery businesses.
Prior to joining Oxitec, he was Chief Executive Officer of
Glide Technologies and led the business to develop a proven
therapeutic delivery platform, generate positive clinical results,
and build a scalable manufacturing line. Before joining Glide
Dr. Carnegie-Brown was General Manager of Zeneca's Agrochemical
business in the United Kingdom and
Ireland where he developed and
implemented a cutting edge value chain strategy and drove
transformation toward an organization attuned to consumers.
He also previously served as Chief Executive Officer of Evolutec
plc, a biological drug development business. Dr.
Carnegie-Brown received a Ph.D. in Applied Biology with a specialty
in pesticide resistance from Manchester University.
Concurrent with Dr. Carnegie-Brown's appointment, Mr. Parry will
move to a broader corporate role to support numerous functions
abroad with specific responsibility for developing and expanding
Intrexon's interests and business opportunities in EMEA. His
business acumen, strong communication skills, and ability to engage
at all levels of business from government to corporations to
consumers will be a key asset to Intrexon.
"It has been a real privilege to lead Oxitec over the last few
years and to help develop such a promising technology into a truly
operational solution that is much needed around the world. I now
look forward to supporting the growth of Intrexon's broader
business," said Mr. Parry.
Randal J. Kirk, Chairman and
Chief Executive Officer of Intrexon, commented, "We welcome Mark at
the helm of Oxitec, the leading engineered insect capability in the
world, and its exemplary team of scientists who are doing so much
to address some of the most pressing needs in human disease vector
control and crop protection against insect pests. And we
welcome Hadyn, who so capably led Oxitec to its world leading
position, to a role of even greater responsibility as he helps us
to expand Intrexon's reach and penetration across multiple
opportunities offering similar impact."
About Oxitec
Oxitec is a pioneer in using
genetic engineering to control insect pests that spread disease and
damage crops, and was founded in 2002 as a spinout from
Oxford University (UK). Oxitec is
a subsidiary of Intrexon Corporation (NYSE: XON), which engineers
biology to help solve some of the world's biggest problems.
Follow us on Twitter at @Oxitec.
About Intrexon Corporation:
Intrexon
Corporation (NYSE: XON) is Powering the Bioindustrial Revolution
with Better DNA™ to create biologically-based products that improve
the quality of life and the health of the planet. Intrexon's
integrated technology suite provides its partners across diverse
markets with industrial-scale design and development of complex
biological systems delivering unprecedented control, quality,
function, and performance of living cells. We call our synthetic
biology approach Better DNA®, and we invite you to
discover more at www.dna.com or follow us on Twitter at @Intrexon,
on Facebook, and LinkedIn.
Trademarks
Intrexon, Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of
Intrexon and/or its affiliates. Other names may be trademarks of
their respective owners.
Safe Harbor Statement
Some of the statements
made in this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more information regarding Intrexon Corporation,
contact:
Investor
Contact:
Christopher
Basta
Vice President,
Investor Relations
Tel: +1 (561)
410-7052
investors@intrexon.com
|
Corporate
Contact:
Marie Rossi,
Ph.D.
Director, Technical
Communications
Tel: +1 (301)
556-9850
publicrelations@intrexon.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intrexon-appoints-dr-mark-carnegie-brown-as-ceo-of-oxitec-300460247.html
SOURCE Intrexon Corporation